» Articles » PMID: 9097952

Murine Mucopolysaccharidosis Type I: Targeted Disruption of the Murine Alpha-L-iduronidase Gene

Overview
Journal Hum Mol Genet
Date 1997 Apr 1
PMID 9097952
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Mucopolysaccharidosis type I (MPS I) is considered to represent the prototypical mucopolysaccharide storage disorder. Although a spectrum of severity is seen within the MPS I subgroup, Hurler syndrome represents the most severe and frequent manifestation of MPS I. We describe here the generation of a murine model for Hurler syndrome by targeted disruption of the murine Idua gene. Homozygous Idua -/- mice have no detectable alpha-L-iduronidase enzyme activity and show increased urinary glycosaminoglycan levels. Although normal appearing at birth, Idua -/- mice develop a flattened facial profile and thickening of the digits discernible by 3 weeks of age. No obvious growth deficiency nor mortality is seen within the first 20 weeks of life. Radiographs reveal anterior flaring of the ribs and thickening of the facial bones as early as 4 weeks of age with more extensive dysostosis detectable by 15 weeks of age. At 4 weeks of age, lysosomal storage is noted primarily within reticuloendothelial cells with abundant lysosomes noted in Kupffer cells, splenic sinusoidal lining cells, and glial cells. More widespread lysosomal storage is noted by 8 weeks of age in hepatocytes, chondrocytes, neurons, as well as renal tubular cells. Thus, targeted disruption of the murine Idua locus has produced a murine strain representative of the severe form of MPS I. This model should permit detailed evaluation of the pathophysiology of lysosomal storage disorders and provide a small animal model for the testing and development of enzyme replacement and gene therapy regimes.

Citing Articles

Endocannabinoid receptor 2 is a potential biomarker and therapeutic target for the lysosomal storage disorders.

Simonaro C, Yasuda M, Schuchman E J Inherit Metab Dis. 2024; 48(1):e12813.

PMID: 39569490 PMC: 11670223. DOI: 10.1002/jimd.12813.


Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA.

Giaccio M, Monaco A, Galiano L, Parente A, Borzacchiello L, Rubino R Mol Ther. 2024; 32(11):4108-4121.

PMID: 39342429 PMC: 11573617. DOI: 10.1016/j.ymthe.2024.09.030.


Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.

Malinowska M, Nowicka W, Kloska A, Wegrzyn G, Jakobkiewicz-Banecka J Int J Mol Sci. 2024; 25(4).

PMID: 38397051 PMC: 10889377. DOI: 10.3390/ijms25042371.


Altered Sphingolipid Hydrolase Activities and Alpha-Synuclein Level in Late-Onset Schizophrenia.

Usenko T, Bezrukova A, Basharova K, Baydakova G, Shagimardanova E, Blatt N Metabolites. 2024; 14(1).

PMID: 38248833 PMC: 10819534. DOI: 10.3390/metabo14010030.


Genetic insight into the putative causal proteins and druggable targets of osteoporosis: a large-scale proteome-wide mendelian randomization study.

Wu Z, Yang K, Lam T, Cheng J, Zhu Z, Lee W Front Genet. 2023; 14:1161817.

PMID: 37448626 PMC: 10336211. DOI: 10.3389/fgene.2023.1161817.